09 Feb Prodesse begins clinical trials for flu virus detection
Waukesha, Wis. – Several major healthcare institutions have begun clinical trials on a flu detection product developed by Prodesse, Inc., a Waukesha-based biotechnology company.
The product, known as ProFlu+, is being billed as a more complete and user-friendly test to help laboratories detect and differentiate several flu viruses, including Influenza A and B and the Respiratory Syncytial Virus.
Prodesse has been working with the Food and Drug Administration to design the clinical studies, and it expects to submit an application for FDA clearance following the completion of the trials this spring.
The company said ProFlu, which is designed for use with existing automated platforms, addresses several shortcomings with existing methods of respiratory virus detection. They include the lack of a clinically useful turnaround time and the need for subjective interpretation.
• Prodesse joins forces with Invitrogen
• Prodesse enters patent agreement with Roche
• Teresa Esser: Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.